Alemtuzumab, total skin electron beam, and non-myeloablative allogeneic haematopoietic stem-cell transplantation in advanced sezary syndrome: a retrospective cohort study

J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e373-e375. doi: 10.1111/jdv.17144. Epub 2021 Feb 13.

Authors

L L Thompson^{1

2}, C X Pan^{1

2}, M S Chang^{1

2}, G E Molina^{1

2}, Y B Chen^{2

3}, J A Barnes^{2

3}, S T Chen^{1

2}

Affiliations

¹ Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

PMID: 33545747
DOI: 10.1111/jdv.17144

No abstract available

Publication types

Letter

MeSH terms

Alemtuzumab / therapeutic use
Electrons
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Retrospective Studies
Sezary Syndrome* / therapy
Skin Neoplasms*

Substances

Alemtuzumab